ZURICH-SCHLIEREN, Switzerland and CONCORD, MA, USA I June 11, 2025 I Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company ...

BASEL, Switzerland I June 12, 2025 I Novartis announced positive results from APPULSE-PNH, a Phase IIIB study evaluating the efficacy and safety of ...

COPENHAGEN, Denmark I June 12, 2025 I SNIPR Biome ApS (“SNIPR”), the company pioneering the development of precision medicines using CRISPR technology for ...

BARCELONA, Spain I June 11, 2025 I SpliceBio, a clinical-stage genetic medicines company pioneering Protein Splicing to address diseases caused by mutations ...

In the completed multiple ascending dose (MAD) portion of the Phase 1/2 open-label HALOS study, ION582 provided consistent and encouraging clinical improvement on all functional domains including ...

SAN DIEGO, CA, USA I June 11, 2025 I Capstan Therapeutics, Inc. (“Capstan”), a clinical-stage biotechnology company dedicated to advancing in vivo ...

Capsida is initiating the Phase 1/2 study for CAP-003, with the first patient expected to be dosed in the third quarter of this year ...

INCHEON, Korea I June 12, 2025 I Samsung Bioepis Co., Ltd. (“Samsung Bioepis”) today presented the long-term safety data of EPYSQLI™ (eculizumab; SB12), a ...

The collaboration combines Salipro Biotech's unique expertise and its Salipro® platform technology to stabilize a challenging drug target and advance ...

CATANIA, Italy I June 10, 2025 I SIFI, a leading international ophthalmic company, today announced that its shareholders have signed an agreement, subject to ...

BERLIN, Germany & CAMBRIDGE, MA, USA I June 11, 2025 I Bayer and the Broad Institute today announced that they have extended their research collaboration ...

STRASBURG, France and CHARLEROI, Belgium I June 11, 2025 I Elkedonia SAS, a company pioneering a novel neuroplastogen approach to develop therapeutic ...